Literature DB >> 8902990

Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease--a preliminary study.

L H Iversen1, M Okholm, O Thorlacius-Ussing.   

Abstract

This study was carried out in order to compare the coagulation balance in patients with colorectal cancer before and after surgical removal of tumor with an age matched non-malignancy control group. Furthermore, it was studied whether preoperative coagulation state in cancer patients was correlated to the postoperative development of deep venous thrombosis (DVT) diagnosed by venography. Plasma was collected preoperatively in 93 cancer patients and 30 controls, and postoperatively on day one, two, seven, and ninety in 88 cancer patients and 18 controls. Prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT), and total fibrin(ogen) degradation products (TDP) were quantitated in plasma by enzyme linked immunosorbent assays (ELISA). As compared to controls, patients admitted for cancer treatment displayed significantly higher levels of F1 + 2 and TAT. Patients suffering from advanced colorectal cancer had significantly higher levels of TAT and TDP as compared to patients with localized colorectal cancer. Twenty-three percent of cancer patients developed DVT postoperatively. Preoperatively these patients displayed significantly higher TDP levels, and postoperatively higher levels of F1 + 2, TAT, and TDP compared to cancer patients without DVT. The marked activation of blood coagulation and fibrinolysis observed in all patients following major abdominal surgery was even more pronounced in patients not cured for cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902990

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Venous thrombosis and cancer: from mouse models to clinical trials.

Authors:  Y Hisada; J E Geddings; C Ay; N Mackman
Journal:  J Thromb Haemost       Date:  2015-06-26       Impact factor: 5.824

2.  Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood.

Authors:  Eric W Klee; Olga P Bondar; Marcia K Goodmanson; Roy B Dyer; Sibel Erdogan; Eric J Bergstralh; H Robert Bergen; Thomas J Sebo; George G Klee
Journal:  Clin Chem       Date:  2012-01-12       Impact factor: 8.327

3.  Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.

Authors:  Dalila Darmoul; Valérie Gratio; Hélène Devaud; Thérèse Lehy; Marc Laburthe
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Imbalance in Coagulation/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy.

Authors:  Marek Z Wojtukiewicz; Marta Mysliwiec; Elwira Matuszewska; Stanislaw Sulkowski; Lech Zimnoch; Barbara Politynska; Anna M Wojtukiewicz; Stephanie C Tucker; Kenneth V Honn
Journal:  Biomolecules       Date:  2021-04-29

Review 5.  A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity.

Authors:  Anne Polk; Kirsten Vistisen; Merete Vaage-Nilsen; Dorte L Nielsen
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-04       Impact factor: 2.483

6.  Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients.

Authors:  Liangliang Zhao; Yayan Bi; Junjie Kou; Jialan Shi; Daxun Piao
Journal:  J Exp Clin Cancer Res       Date:  2016-03-25

Review 7.  Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.

Authors:  Freesia Horsted; Joe West; Matthew J Grainge
Journal:  PLoS Med       Date:  2012-07-31       Impact factor: 11.069

8.  Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.

Authors:  C C Kirwan; G McDowell; C N McCollum; S Kumar; G J Byrne
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.